首页> 美国卫生研究院文献>AMIA Summits on Translational Science Proceedings >On the Bayesian Derivation of a Treatment-based Cancer Ontology
【2h】

On the Bayesian Derivation of a Treatment-based Cancer Ontology

机译:基于治疗本体论癌症的贝叶斯推导

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Traditional cancer classifications are primarily based on anatomical locations. As knowledge is heavily compartmentalized in the oncological specialties, discovering new targets for existing drugs (drug inference) can take years. Furthermore, our lack of understanding of the mechanisms underlying drug efficacy sometimes undercuts the effectiveness of genetic approaches to drug inference. This study tackles the twin problems of cancer reclassification and drug inference by constructing a global cancer ontology inductively from treatment regimens. A topological abstraction algorithm was performed on the bipartite graph of drugs and cancers to highlight important edges, and a Bayesian algorithm was then applied to determine a new treatment-based classification of cancer, producing 6 highly significant clusters (p < 0.05), confirmed by Fisher’s exact test and enrichment analyses. Edge probabilities derived from its drug inference routine matched real edge frequencies (R2 ≈ 0.96). Drug inference results were reinforced by the identification of relevant published Phase II and III clinical trials, and the drug inference routine differentiated between high- and low-likelihood targets (p < 0.05). This novel treatment-based ontology has the potential to reorganize cancer research and provide powerful tools for drug inference using global patterns of drug efficacy.
机译:传统的癌症分类主要基于解剖位置。由于肿瘤专科知识被高度隔离,因此发现现有药物的新靶标(药物推论)可能需要数年时间。此外,我们对药物功效基础机制的缺乏理解有时会削弱遗传方法对药物推论的有效性。这项研究通过从治疗方案中归纳构建全球癌症本体论,解决了癌症分类和药物推断的双重问题。在药物和癌症的二部图上执行拓扑抽象算法以突出显示重要的边缘,然后将贝叶斯算法应用于确定基于治疗的新癌症分类,产生6个高度显着的簇(p <0.05),证实为费舍尔的精确测试和富集分析。由其药物推导程序得出的边缘概率与实际边缘频率匹配(R2≈0.96)。通过鉴定相关的已发表的II期和III期临床试验,加强了药物推论的结果,并且将药物推论的常规区分了高可能性目标和低可能性目标(p <0.05)。这种新颖的基于治疗的本体论具有重组癌症研究的潜力,并提供了使用整体药物疗效模式进行药物推断的强大工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号